Piramal Pharma expects the current financial year (FY 2027) to see a revival in growth, even as geo-political uncertainties continue to cast a shadow on industry segments including pharmaceuticals.
“FY27 will be a return to growth,” Piramal Pharma Chairperson, Nandini Piramal told businessline, in a post-results interaction. “FY26 was a transitional year, shaped by external disruptions and certain business-specific factors. Despite these challenges, we exited the year on a stronger note, with clear momentum across all our businesses,” she said.
There has been a recovery in biopharma funding from September 2025, and this was translating into good RFP (request for proposal) momentum and a healthy pick up in order inflows in the CDMO (contract development and manufacturing organisation) business, she said. “In the CHG (complex hospital generics) business, the recently completed Kenalog acquisition alongside ramp up of inhalation anesthesia sales in ex-US markets are expected to be key growth drivers. Our Consumer Healthcare business is also well positioned to sustain its growth momentum with margin improvement driven by Power Brands and rapid growth in e‑commerce,” she added.
Three businesses
All three businesses are well positioned to deliver growth in FY27, she said, accompanied by accelerated growth in EBITDA and PAT.
The company’s revenue from operations stood at ₹2752 crore for the fourth quarter ended March 31, 2026, as compared to ₹2754 crore in the same period last year. It posted a ₹9 crore loss, impacted by an impairment cost of ₹176 crore linked to assets under development. “Based on a reassessment incorporating changes in market conditions and updated commercial viability estimates, management concluded that the probable future economic benefits from the asset are no longer expected to be adequate to justify further capital deployment. Accordingly, the carrying amount has been written down in full,” the company said.
The company closed FY 26 with revenue from operations at ₹8869 crore, compared to ₹9151 crore last year. Its net loss after tax after exceptional item stood at ₹326 crore., for the year. On the geo-political uncertainty, she said, until now, those costs have been manageable. “If it continues for much longer, anything that is petrochemical-derived will show increases in prices. And it will be on a product-by-product basis to see what, how we can share the pain. …It is something that we have our eye on. We’re trying to mitigate it, but it will be literally on a product-by-product level,” she said.